We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Genetic Screening Should Focus on People with Cancer

By LabMedica International staff writers
Posted on 21 Oct 2008
Genetic screening should focus on testing young people who develop bowel cancer to determine if it was caused by an inherited genetic fault that might be shared by other family members. More...
This could effectively halve deaths caused by an inherited form of bowel cancer.

Bowel cancer is one of the most common forms of cancer in Australia. There are about 1,000 cases each year diagnosed in people under the age of 50, and about 10% of these (100 per year) are the result of genetic fault that can now be detected.

"If we redirect the emphasis of our genetic screening programs to focus more on people who already have cancer we can make a really big difference,” said Prof. Hopper, an Australia Fellow of the National Health and Medical Research Council in the Melbourne School of Population Health at the University of Melbourne (Parkville, Australia). "We can work with patients to help prevent them developing new cancers, or at least detect them at an early stage, and we can arm their families with the knowledge to help save lives.”

A similar approach could also be taken to improve genetic testing for breast cancer by studying the tumors of young women who developed the disease. "Breast cancers arising in young women with an inherited fault in BRCA1 have particular features that pathologists can easily identify.” said Prof. Hopper. "Women with an inherited fault in BRCA1 have about a 60% lifetime risk of developing breast cancer, and a 40% lifetime risk of developing ovarian cancer.”

However, it would still be appropriate to offer genetic testing to people with a very strong family history of breast or bowel cancers, especially if it involved diagnoses before the age of 50.

Related Links:
University of Melbourne Medical School



Gold Member
Quality Control Material
iPLEX Pro Exome QC Panel
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Homocysteine Quality Control
Liquichek Homocysteine Control
ESR Analyzer
TEST1 2.0
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: Residual leukemia cells may predict long-term survival in acute myeloid leukemia (Photo courtesy of Shutterstock)

MRD Tests Could Predict Survival in Leukemia Patients

Acute myeloid leukemia is an aggressive blood cancer that disrupts normal blood cell production and often relapses even after intensive treatment. Clinicians currently lack early, reliable markers to predict... Read more

Pathology

view channel
Image: The AI tool advances precision diagnostics by linking genetic mutations directly to disease types (Photo courtesy of Shutterstock)

AI Tool Simultaneously Identifies Genetic Mutations and Disease Type

Interpreting genetic test results remains a major challenge in modern medicine, particularly for rare and complex diseases. While existing tools can indicate whether a genetic mutation is harmful, they... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.